Blood sugar is difficult to control? Stem cell therapy brings new hope September 09, 2015 Source: Health Network At present, the treatment of diabetes does not address the key link of the disease. It can only relieve or relieve the symptoms, delay the progression of the disease, and cannot cure the disease fundamentally. Stem cells are a new hope for the treatment of diabetes, and stem cell treatment of diabetes has also become a research hotspot. Stem cells are further divided into embryonic stem cells (ES) and adult stem cells. Since ES cells have a series of problems including ethics, there is no relevant clinical research. Among adult stem cells, the most commonly used in clinical research is mesenchymal stem cells (MSC). It is well known that type 1 diabetes is caused by beta cell destruction caused by autoimmune inflammation of islet β cells, while type 2 diabetes is the result of a combination of impaired islet β cell function and insulin resistance. Therefore, the ideal strategy for curing diabetes must be directed to the above key links. Studies by the team of mother professors show that MSC has both of these effects: through its secretory effects, it reduces chronic inflammation, promotes the conversion of macrophages to anti-inflammatory M2 macrophages, and reduces insulin resistance through miRNAs in exosomes; Promote b cell autophagy, promote the transformation of alpha cells to beta cells to protect b cells, and promote b cell regeneration. Under the combined effect of both sides, the hypoglycemic effect is produced. In addition to exploring the mechanisms of MSC treatment of diabetes, Professor Yiyi Ming also carried out the following work: large sample, multi-center clinical trial development; establishment of optimal transplantation protocol; establishment of in vitro culture conditions; implementation of appropriate pretreatment protocol; MSC Mechanism analysis to promote in situ regeneration of b cells. (Professor Yiyi Ming will share his latest research results at the 2015 (7th) Stem Cell Technology and Clinical Transformation Forum held in Shanghai 11.5-6. Welcome to register!) The results are as follows: Clinical Trials Umbilical cord Huatong mesenchymal stem cells (UC-MSCs) infusion for the treatment of multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of insulin-treated patients with type 2 diabetes in China with poor glycemic control ( Currently enrolled in half of the patients). Pre-experimental results show that MSC can effectively reduce the amount of insulin used in T2DM patients and reduce the level of HbA1c at 24 weeks. Optimal transplantation plan Multiple early infusions are beneficial to the efficacy of MSC transplantation in the treatment of type 2 diabetes. In vitro culture conditions The umbilical cord Wharton's Jelly was used for the aging of mesenchymal stem cell senescence. The coating of WJE significantly reduced the aging of MSCs accompanying passage in vitro and maintained its multiple differentiation ability. Pretreatment scheme In vitro and in vivo experiments confirmed that high glucose pretreated MSCs had significant repair effects on glycotoxic induced islet b cell function damage. Mechanism of MSC promoting B cell in situ regeneration After STZ injection, islet a cells were transdifferentiated into b cells after epithelialization. Finally, the mother professor pointed out that the future development direction of MSC has the following five aspects: 1. long-term safety and effectiveness; 2. standardization of in vitro isolation and culture of MSC; 3. standardization of MSC status; 4. treatment of diabetes The source and species of optimal mesenchymal stem cells; 5. Analysis of the regulation of the systemic immune system. 8 Inch Biometric Tablet,Industrial Rugged Android Tablet,Portable Fingerprint Tablet,Rugged Portable Time Attendance Tablet Shenzhen BIO Technology Co.,Ltd. , https://www.hfsecuritytech.com